The DEA administrative process for moving botanical marijuana from Schedule I to Schedule III remains in a limited briefing phase following an October 22 order from Chief ALJ Derek Julius. That ruling admitted a September GAO report highlighting gaps in federal scheduling procedures but denied requests to reopen the June-July 2026 hearings for additional testimony. Optional briefs on the report’s weight are due by November 5, after which the stay lifts and the judge can issue a nonbinding recommendation. An April 2026 Attorney General order already placed state-licensed medical marijuana and FDA-approved products into Schedule III, with the DEA issuing initial federal registrations to over 900 dispensaries in seven states as the first implementation step. Broader rescheduling covering adult-use cannabis requires the full hearing record, agency decision, and potential further review, keeping near-term resolution unlikely.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật1H6H1D7D30DALL
View resolved

Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp